Drug Trial Radar · NCT07663526
Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Sep 23, 2026
Primary completion
Dec 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a post-marketing real-world study designed to evaluate the efficacy and safety of Tabellvi® (Adalimumab Injection) in Chinese adult subjects with moderate to severe active Crohn's disease via a single-arm trial. A total of 50 subjects are planned to be enrolled. The primary endpoints include the incidence rates of adverse events (AEs), serious adverse events (SAEs), adverse drug reactions (ADRs) and serious ADRs, as well as the proportion of subjects achieving clinical remission (CDAI score \< 150) at Week 26.
Conditions
- Crohn's Disease
Interventions
TyboWe® Adalimumab InjectionDrug
Adalimumab is a human anti-tumour necrosis factor-alpha monoclonal antibody that inhibits the downstream inflammatory cascade by blocking TNF-α, a core inflammatory factor in psoriasis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serious Adverse Event (SAE)Time frame: Baseline up to 54 weeks
- Adverse Event (AE)Time frame: Baseline up to 54 weeks
- Adverse Drug Reaction (ADR)Time frame: Baseline up to 54 weeks
- Serious Adverse Drug ReactionTime frame: Baseline up to 54 weeks
- Clinical remission (CDAI < 150)Time frame: At Week 26 post-dose
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Fuyang People's Hospital
Fuyang, Anhui, China · Not yet recruiting
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
Zhoukou Central Hospital
Zhoukou, Henan, China · Not yet recruiting
Huai'an First People's Hospital
Huaian, Jiangsu, China · Not yet recruiting
Yancheng No.1 People's Hospital
Yancheng, Jiangsu, China · Not yet recruiting
Meihekou Central Hospital
Meihekou, Jilin, China · Not yet recruiting
Shanghai Jiao Tong University School of Medicine, Renji Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.